D. E. Shaw & Co., Inc. Allakos Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $1.1 Million - $1.54 Million	-10,000 Reduced 63.29%	5,800 $666,000
Q4 2020 Feb 16, 2021	SELL	$79.58 - $152.45 $795,800 - $1.52 Million	-10,000 Reduced 38.76%	15,800 $2.21 Million
Q3 2020 Nov 16, 2020	BUY	$66.43 - $90.99 $385,294 - $527,742	5,800 Added 29.0%	25,800 $2.1 Million
Q4 2019 Feb 14, 2020	BUY	$66.49 - $137.73 $1.33 Million - $2.75 Million	20,000 New	20,000 $1.91 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $74.6M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.